ArticleFrontiers in oncology2026
Treatment of extracranial rhabdoid tumor with intensive ifosfamide-containing chemotherapy regimens.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Extracranial malignant rhabdoid tumors (MRT) and rhabdoid tumors of the kidney (RTK) are rare pediatric solid tumors characterized by aggressive behavior and poor prognosis. Case reports have demonstrated successful outcomes using ifosfamide-containing chemotherapy regimens, leading some clinicians to incorporate this alkylating agent into treatment plans. We assessed our institutional experience treating MRT and RTK using ifosfamide-containing regimens. Methods: Fifteen patients with histologically confirmed MRT or RTK and loss of INI1 who were treated at Children's National Hospital (CNH) between 2009 and 2025 were reviewed retrospectively. Results: The median age at diagnosis was 16 months (range: 3-171 months). Eleven patients (73.3%) had MRT and four (26.7%) had RTK. Treatment involved multimodal therapy, including surgical resection when feasible, radiation therapy, and intensive chemotherapy. Eleven patients received regimens including ifosfamide, in some cases with higher-dose cyclophosphamide compared to recent Children's Oncology Group and European Soft Tissue Sarcoma Study Group protocols. Three-year event-free survival (EFS) and overall survival (OS) were 42.4% (95% CI: 22.7-79.3%) and 40.4% (95% CI: 20.8-78.5%), respectively. No significant difference in 3-year EFS was observed with ifosfamide (43.6%, 95% CI: 21.8-87.4%) versus without ifosfamide (37.5%, 95% CI: 8.4-100%; p=0.85). Second and third-line treatment regimens included tazemetostat (n=3), temozolomide/irinotecan +/- vincristine (n=3), alisertib (n=1), and cemiplimab (n=1); however, no responses were observed. Conclusion: Ifosfamide-containing regimens did not appear to improve outcomes for MRT or RTK. Novel, targeted therapeutic strategies are urgently needed to improve survival for patients with rhabdoid tumor, particularly those with stage III/IV disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.